장마감
로그인 회원가입
STVN
STVN
Stevanato Group Spa
7월 27일 4:00 PM ET (한국 7/28 05:00)
$19.80
+0.12 ▲ +0.61%
🌙 7월 27일 5:54 PM ET (한국 7/28 06:54)
$19.66
-0.14 ▼ -0.71%

스테바나도 그룹(STVN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$5.4B
스몰캡
P/E
33.0
적정 수준
배당수익률
0.27%
52주 위치
46%
저점 +54% · 고점 -29%
애널리스트
적극 매수
B-
Fundamental health
vs. Medical Instruments & Supplies
수익성 ⓘ
Top 31%
성장 ⓘ
Top 47%
밸류에이션 ⓘ
Top 37%
재무 안정 ⓘ
Top 48%
Index ⓘ -P/E ⓘ 32.96EPS (ttm) ⓘ 0.6Insider Own ⓘ 81.79%Shs Outstand ⓘ 49.7MPerf Week ⓘ 3.39%
Market Cap ⓘ 5.41BForward P/E ⓘ 24.14EPS next Y ⓘ 18.95%Insider Trans ⓘ -Shs Float ⓘ 49.7MPerf Month ⓘ 7.67%
Enterprise Value ⓘ 5.79BPEG ⓘ 1.43EPS next Q ⓘ 0.14Inst Own ⓘ 16.9%Short Float ⓘ 1.94%Perf Quarter ⓘ 22.37%
Income ⓘ 0.16BP/S ⓘ 3.87EPS this Y ⓘ 12.1%Inst Trans ⓘ -2.07%Short Ratio ⓘ 2.49Perf Half Y ⓘ 14.65%
Sales ⓘ 1.40BP/B ⓘ 3.06EPS next 5Y ⓘ 16.89%ROA ⓘ 5.98%Short Interest ⓘ 0.97MPerf YTD ⓘ -1.59%
Book/sh ⓘ 6.46P/C ⓘ 42.01EPS past 3/5Y ⓘ 0.64% 11.33%ROE ⓘ 9.96%52W High ⓘ -29.29% ($28.00)Perf Year ⓘ -25.31%
Cash/sh ⓘ 0.47P/FCF ⓘ 933.59Sales past 3/5Y ⓘ 9% 12.15%ROIC ⓘ 7.68%52W Low ⓘ 53.61% ($12.89)Perf 3Y ⓘ -35%
Dividend Est. ⓘ $0.05 (0.27%)EV/EBITDA ⓘ 17.41EPS Y/Y TTM ⓘ 21.77%Gross Margin ⓘ 28.1%Volatility(W/M) ⓘ 3.48% 4.5%Perf 5Y ⓘ -0.5%
Dividend TTM ⓘ 0.06EV/Sales ⓘ 4.15Sales Y/Y TTM ⓘ 15.54%Oper. Margin ⓘ 16.26%ATR (14) ⓘ 0.82Perf 10Y ⓘ -
Dividend Ex-Date ⓘ 2026/6/11Quick Ratio ⓘ 1.11EPS Q/Q ⓘ 17.4%Profit Margin ⓘ 11.76%RSI (14) ⓘ 59.36Recom ⓘ 1.33
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 1.63Sales Q/Q ⓘ 18.52%SMA20 ⓘ 2.97% ($19.23)Beta ⓘ 0.76Target Price ⓘ $24.25
Payout ⓘ 10.76%Debt/Eq ⓘ 0.29Earnings ⓘ 2026/8/4SMA50 ⓘ 7.78% ($18.37)Rel Volume ⓘ 0.91Prev Close ⓘ $19.68
Employees ⓘ -LT Debt/Eq ⓘ 0.21EPS/Sales Surpr. ⓘ 6.16% 2.37%SMA200 ⓘ 5.12% ($18.84)Avg Volume(3M) ⓘ 0.39MPrice ⓘ $19.8
IPO ⓘ 2021/7/16Option/Short ⓘ Yes/YesTrades ⓘ 3741Volume ⓘ 353,730Change ⓘ 0.61%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Stevanato Group Spa (STVN) Investment Analysis

What kind of company is Stevanato Group Spa?

스테바나도 그룹(STVN) 성장주
Healthcare · Medical Instruments & Supplies
#1349 by Market Cap — Mid-Cap

💉 This Italian company manufactures glass containers and drug delivery systems for the pharmaceutical and biotech industries. It supplies pharmaceutical firms with glass containers such as vials, syringes, and cartridges, as well as drug delivery devices including prefilled syringes and injection pens. As a medical device stock, its performance is closely tied to pharmaceutical production and injectable drug demand.

Learn more about Stevanato Group Spa →
Market Cap
$5.4B
Approx. KRW 7.4 trillion
⚖️ 2% of Samsung Electronics
Market Cap Rank1349
IPO2021/07/16
Current Price$19.80 ≈ 27,126원
NYSE · Italy

Key Events

⏰ Upcoming events
🔔 Earnings release D-8
8월 4일 (화) · 장 시작 전
예상 EPS $0.14
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🎯 Ex-div 2026년 6월 11일 (목) 주당 $0.054
🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS +6.2% 매출 +2.4%
🔔 Earnings release 2026년 3월 4일 (수) · 장 시작 전 EPS +5.3% 매출 +2.1%
🎯 Ex-div 2025년 6월 5일 (목)

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
16.3%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies Median 5.5% · Top 22%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
11.8%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies Median -5.3% · Top 22%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
28.1%
✓ 부진
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies Median 48.6% · Bottom 25%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
10.0%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 중형주 Median -17.0% · Top 25%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
6.0%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 중형주 Median -9.3% · Top 21%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
7.7%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 중형주 Median -11.9% · Top 20%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.29
✓ Healthy debt
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 0.26
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
1.63
✓ 양호
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 2.34
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.11
✓ 양호
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 1.97
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$24.25
현재가 대비 +22.5%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
24.14배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
1.43
적정
💡 PEG 1~1.5 — 성장 대비 합리적
내년 EPS 예상 성장률
+18.9%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+16.9%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+7.7%
평균 서프라이즈
2026.05.07
상회
실적 $0.13 · 예상 $0.12 +8.6%
2026.03.04
상회
실적 $0.21 · 예상 $0.20 +6.9%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+12.1%
평균
My positionMid-range
Low range Average High range
성장주 중형주 Median 13.7% · Bottom 44%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+18.9%
양호
My positionMid-range
Low range Average High range
성장주 중형주 Median 15.1% · Top 36%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+16.9%
양호
My positionMid-range
Low range Average High range
성장주 중형주 Median 15.9% · Top 45%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+0.6%
평균
My positionMid-range
Low range Average High range
성장주 중형주 Median 8.2% · Bottom 39%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+11.3%
평균
My positionMid-range
Low range Average High range
성장주 중형주 Median 13.1% · Bottom 47%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+12.2%
양호
My positionMid-range
Low range Average High range
성장주 중형주 Median 10.6% · Top 44%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+18.5%
양호
My positionMid-range
Low range Average High range
성장주 중형주 Median 11.1% · Top 32%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -69%p below the market
STVN -0.5% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-68.8%p
Significantly behind the market
vs Health Care (XLV)
-25.0%p
behind the sector average
1-year basis
vs S&P 500
-41.3%p
Significantly behind the market
vs Health Care (XLV)
-45.0%p
Significantly behind the sector average
Rank among peers
5-year return Top 24% Based on 10 peers
1-year return Lowest among peers Based on 12 peers
Current position within 52-week range
Low (-53.6%p) High (-29.3%p)
Current price is 53.6% above the 52-week low and 29.3% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-23.3%
Annualized volatility
50.6%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-27
Uptrend zone

Current price $19.80 above the midline ($19.23). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD 0.417 · Signal 0.435 · Hist -0.018. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 59.4 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 69.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
Cheap on Vs. Earnings, Pricey on Vs. Cash Flow, In line with peers on Vs. Assets·Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Mid-range
🧾 Vs. Sales Mid-range
💧 Vs. Cash Flow Pricey
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
32.96x
✓ Cheap
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 35.22x · Around the industry average
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
24.14x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 18.44x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
3.06x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 2.71x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
3.87x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 2.92x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
17.41x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 14.76x · Around the industry average
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
933.59x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Medical Instruments & Supplies median 25.16x · Bottom 1% — expensive within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$24.25 vs. current price +22.5%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Medical Instruments & Supplies

Who owns it?

Ownership is broadly stable
Institutional net selling -2.1% · Short interest light 1.9% · Short interest fell -1.2%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-2.1%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 16.9%
Retail-led
Healthcare 중형주 Median 89.4%
🧑‍💼 Insiders 81.8%
Founder/management large holders (strong skin-in-the-game)
Healthcare 중형주 Median 9.4%
👤 Retail investors (estimated) 1.3%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
1.9%
Low — limited short-side pressure
Healthcare 중형주 Median 11.3%
Past 90 days 📉 -1.2%p decrease
Short interest days to cover
2.5 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 49.7M주
Float (tradable shares) 49.7M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding STVN

ETFs with the highest weightings · 10 total shown
BCSM
BCSM
Baron SMID Cap ETF
1.33%
$32M
BCGD
BCGD
Baron Global Durable Advantage ETF
0.97%
$10M
APPC
APPC
Corgi APP 2x Daily ETF
0.94%
NBSM
NBSM
Neuberger Small-Mid Cap ETF
0.84%
$114M
XEUR
XEUR
Corgi Europe Equities 2x Daily ETF
0.67%
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당 지급 — 연 0.27%
배당보다 주가 성장에 가까운 비중
Dividend Yield
0.27%
Industry average 1.23%
Dividend Per Share
$0.05
Annualized
Payout Ratio
11%
Share of net income paid as dividends
5-Year Growth
-
Annualized dividend growth
📊 총 이력 2022~2025 (4건)
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$0.05
2022
$0.06 +7.4%
2023
$0.06 +0.0%
2024
$0.06 +6.9%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 4건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2025-06-05
$0.062
—
0.27%
2024-06-04
$0.058
—
0.61%
2023-06-07
$0.058
—
0.40%
2022-06-13
$0.054
—
0.36%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 2,146원
5년 누적 (세후) 1.1만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
STVN STVN This Stock
$5.4B33.0 ▼3.1 ▼9.96% ▲0.27% ▼+0.6%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
스테바나토 그룹(STVN) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
스테바나토 그룹(STVN)은 제약·바이오용 유리 용기와 약물 전달 시스템을 생산하는 이탈리아 기업으로, 주사제 수요와 고부가 제품 비중, 생산 능력 확충과 원가에 실적과 주가가 연동되며, 바이오·주사제 수요 노출이 특징인 의료기기 종목입니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 스테바나도 그룹(STVN)?

스테바나도 그룹(STVN) belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is the market cap of STVN?

The market cap of STVN is approximately $5.4B, ranking 1,349 within its sector.

Does STVN pay dividends?

STVN has a dividend yield of approximately 0.27%, with an annual dividend of $0.05.

What is the P/E ratio of STVN?

STVN has a P/E ratio of approximately 33.0x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for STVN?

STVN has recorded a 52-week high of $28.00 and a low of $12.89.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.